Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Examining the recent TRITON3 Phase 3 Clinical Data of Rubraca (rucaparib) from Clovis Oncology for the Treatment of Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations.

Ticker(s): CLVS

Who's the expert?

A urologic oncologist who manages many patients with mCRPC and is familiar with the phase 3 data from the TRITON3 trial regarding Rubraca.

Interview Goal

To gain increased insight into the potential use of Rubraca (rucaparib) in the treatment of metastatic Castration-Resistant Prostate Cancer with an emphasis on the recent release of phase 3 data from the TRITON3 clinical trial.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here To Join
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here To Join
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.